Kornimate/medical-research-clean huggingface dataset:
accuracy of core body temperature measurement depending on oesophageal probe tip location

Conditions: Emergencies; Hypothermia

Summary: background an accurate measurement of the core body temperature (cbt) is of pivotal importance in the management of severely hypothermic patients. for instance, triage decisions for or against extracorporeal rewarming of hypothermic patients in cardiac arrest strongly depend on cbt. cbt measurement with an oesophageal probe is currently considered the gold standard in hypothermic patients with a secured airway in the prehospital setting, with the tip of the probe placed into the distal third of the oesophagus (i.e., posteriorly to the heart and distal to the tracheal bifurcation). however, the correct placement of the probe tip cannot be verified in the prehospital setting, and it is unknown how incorrect placement affects temperature readings. hypothesis and aim the investigators hypothesise that an incorrect placement of the oesophageal temperature probe tip could lead to inaccurate measurements (i.e., temperature readings not reflecting the real cbt). particularly, a tip location too high in the oesophagus in close proximity to the trachea could lead to falsely low temperature readings, especially when the patient is ventilated with cold air. the aim of the proposed study is to investigate the influence of oesophageal temperature probe tip location on cbt measurement. methods experimental, interventional study on 16 healthy volunteers. during the test oesophageal temperature is measured while participants are breathing ambient air first at 20°c (baseline) followed by cold (-20°c) ambient air in supine position for 20 minutes each test in an environmental simulator (terraxcube). each participant repeats the 20-min test two times with the oesophageal temperature probe tip placed either in the lower third of the oesophagus (i.e., correct position) or too high in the oesophagus, i.e. behind the trachea.


Eligibility criteria:
inclusion criteria: * volunteers with an american society of anaesthesiologists (asa) score ≤2. exclusion criteria: * asa \>3 * age \ 75 * pregnant women * no signed informed consent * signs and symptoms of an acute illness on the study day * history of oesophageal and nasopharyngeal disorders * allergies to local anaesthetics (i.e. lidocain).
ehealth mindful movement and breathing in improving outcomes in participants undergoing gynecologic surgery

Conditions: Female Reproductive System Neoplasm; Malignant Female Reproductive System Neoplasm; Malignant Uterine Neoplasm; Ovarian Carcinoma; Ovarian Neoplasm; Suspicious for Malignancy; Uterine Neoplasm

Summary: this trial determines how well ehealth mindful movement and breathing works to improve outcomes in participants undergoing gynecologic surgery. supportive therapy, such as ehealth mindful movement and breathing, uses techniques that include gentle movements, breathing, and relaxation techniques which may help participants cope with and improve their surgical experiences.

primary objectives: i. to field-test implementation strategies of the mindful movement and breathing (emmb) intervention that has been adapted to the ehealth format. outline: participants receive a self-directed 20-minute emmb video and are instructed to practice emmb at least once before surgery and daily for 2 weeks after surgery. participants may also request additional guidance from a yoga instructor via telephone and video conference before surgery and again 1 day after surgery or as soon as feasible. after completion of study, participants are followed up at 4 weeks from surgery.

Eligibility criteria:
inclusion criteria: * scheduled for an abdominal gynecological surgery (i.e. uterine, ovarian) to remove a mass that is suspected to be malignant * have an eastern cooperative oncology group (ecog) performance status of ≤1 * cognitively able to complete assessments as judged by the study team * able to understand, read and write english exclusion criteria: * have schizophrenia or any other psychotic disorder * have a diagnosed sleep disorder including untreated obstructive sleep apnea, periodic limb movement disorder, or restless leg syndrome
retrospective observational evaluation of the bone mineral density outcome in young women with amenorrhea

Conditions: Amenorrhea

Summary: the study aims to evaluate the outcomes of different estrogen therapy regimens in patients with amenorrhea who face prolonged periods of hypoestrogenism. the primary objective is to compare the outcomes on bone mass of different therapeutic regimens and identify more favorable. for this purpose, densitometry parameters such as bmd, t-score and z-score at the level of the lumbar spine, femur and entire skeleton will be considered, comparing a bone densitometry (dxa technique, dual x-ray absorptiometry) baseline with one carried out after at least one year of therapy. the secondary objective of the study is to assess other systemic/metabolic implications of the different therapies.

the present retrospective monocentric observational study involves the recruitment of patients afferite at the u.o. of gynecology and physiopathology of human reproduction in the time interval between 2011 and 2020 in condition of amenorrhea greater than 6 months, aged between 15 and 39 at the time of first visit. patients will be asked to participate in this study during the outpatient follow-up visit. the study will involve data collection through consultation of health records. the objectives of the study will therefore be achieved by analysing the following parameters, which can be fully deduced from the medical records of the subjects in the study: * collection of anamnestic (eating habits and sports, pathologies of note, taking drugs, previous surgical interventions, smoking habit, gynecological history). * physical examination: calculation of bmi, acne and hirsutism score (gags and ferriman score), blood pressure measurement, gynecological physical examination * transvaginal or transabdominal pelvic ultrasound * lumbar, femoral, total body dual-energy x-ray absorptiometry (dxa) * blood tests (blood count, lipid profile, glycemic, liver, kidney, hormonal status) * reports of other visits and specialist examinations performed by the patients brought to view during the visit

Eligibility criteria:
inclusion criteria: * patients who have presented themselves to the o.u. of gynecology and human reproduction pathophysiology in the period from 2011 to 2020 with amenorrhea over 6 months, and aged between 15 and 39 years at the time of the visit. * patients who have reached the age of 18 at the time of surgery. * patients for whom informed consent has been obtained. exclusion criteria: no exclusion criteria are provided.

Keywords: amenorrhea bone mass estrogen therapy
outcomes of frozen shoulder treated with small needle-knife through microcirculation and pulse analysis.

Conditions: Frozen Shoulder

Summary: the aim is to investigate whether adding small needle-knife therapy to standard western medicine enhances the treatment of frozen shoulder by evaluating its impact on microcirculation and meridian unblocking.

the aim of this research is to investigate whether the combination of small needle-knife therapy with conventional western medicine treatment can enhance therapeutic effects compared to conventional treatment methods. in addition to clinical measurements of joint mobility and relevant scales, this study integrates instruments such as laser doppler flowmetry (ldf) and pulse diagnosis devices. these non-invasive methods are employed to evaluate the microcirculation performance of patients with frozen shoulder before and after conventional western medicine treatment or combined treatment with small needle-knife therapy. the objective is to understand the effects of small needle-knife therapy on the microcirculation and meridian unblocking in frozen shoulder patients.

Eligibility criteria:
inclusion criteria: * limited shoulder joint mobility in various angles (forward flexion, abduction, external rotation, and internal rotation), persisting for over two months. * persistent pain on the affected shoulder even without rest. * willing and consenting to participate in this research. exclusion criteria: * degenerative shoulder joint arthritis (osteoarthritis). * rheumatoid arthritis. * fracture of the humerus, clavicle, scapula, shoulder acromioclavicular dislocation, shoulder dislocation. * cervical radiculopathy. * thoracic outlet syndrome. * restricted shoulder joint mobility due to stroke, spinal cord injury, or other factors.

Keywords: frozen shoulder acupotomy small needle-knife adhesive capsulitis laser doppler flowmetry photoplethysmography blood pressure waveform
effect of caudal nalbuphine on postoperative analgesia in children

Conditions: Postoperative Pain

Summary: nalbuphine as an adjuvant to bupivacaine caudal anesthesia for postoperative analgesia in children undergoing hypospadias repair. 2 groups, 30 patients each


Eligibility criteria:
inclusion criteria: * children undergoing elective hypospadias repair * with american society of anesthesiologists (asa) physical status i * age 2-10 years exclusion criteria: * coagulation disorder * allergy to study medications * major malformations of the lower spine or meninges or any cutaneous or subcutaneous lesion at the site of injection.
study to assess efficacy and safety relative to standard of care in patients with covid-19 pneumonia

Conditions: COVID-19; Pneumonia

Summary: to assess the clinical efficacy of ang-3777 relative to the standard of care in reducing the severity and progression of pulmonary and renal dysfunction and mortality in adult patients hospitalized with covid-19 pneumonia


Eligibility criteria:
inclusion criteria: 1. patient is a male or nonpregnant female 18 years of age or older. 2. patient has a positive reverse-transcriptase-polymerase-chain-reaction (rt-pcr) assay for sars-cov-2 in a respiratory tract sample during the current hospital admission. 3. patient has pneumonia confirmed by chest imaging. 4. patient has moderate to severe disease based on the who disease severity scale assessment at the time of randomization defined as: * score 4, only those with fio2 \> 40% * score 5 (non-invasive ventilation or high-flow oxygen) 5. patient has ability to provide informed consent signed by study patient or legally acceptable representative. 6. patient has willingness and ability to comply with study-related procedures/assessments exclusion criteria: 1. has an active malignancy or history of solid or hematological malignancies within 5 years prior to enrollment in the study. patients who had basal or squamous cell carcinoma-in-situ of the skin that was diagnosed \> 2 years prior to the study enrollment and not currently being treated are eligible for study enrollment. 2. patient is pregnant or breast-feeding. 3. patient, in the opinion of the investigator, is unlikely to survive for ≥48 hours from the time of screening. 4. patient has any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study. 5. patient with alanine aminotransferase (alt) or aspartate transaminase (ast) \> 3x upper limit of normal (uln) and/or total bilirubin \> 2xuln at baseline 6. patient requires treatment with the cytochrome p450 1a2 (cyp1a2) inhibitors, ciprofloxacin (cipro®) and/or fluvoxamine (luvox®) 7. patients participating in any other clinical trial with an investigational drug product or procedure 8. recipients of solid organ and/or hematopoietic cell transplantation 9. patient is known to have end stage renal disease (esrd) and was being treated with maintenance hemodialysis or peritoneal dialysis prior to the current hospitalization. note: patients who initiated rrt due to acute kidney injury during their current hospitalization will be eligible for the study

Keywords: covid-19 acute lung injury acute respiratory distress syndrome pneumonia respiratory failure aki
pegteograstim in children with solid tumors

Conditions: Chemotherapy Induced Neutropenia; Pediatric Solid Tumor

Summary: to evaluate the efficacy and safety of pegteograstim on chemotherapy-induced neutropenia in children with solid tumors

children with solid tumor experience neutropenia after cytotoxic chemotherapy, and they usually receive granulocyte colony-stimulating factor (g-csf) to stimulate neutrophil recovery. however it needs daily injection of g-csf. pegteograstim is a new formulation of pegylated recombinant human g-csf analogue pegfilgrastim. in this study, investigators aimed to evaluate the efficacy and safety of pegteograstim on chemotherapy-induced neutropenia in children with solid tumors.

Eligibility criteria:
inclusion criteria: * patients with solid tumor who undergo chemotherapy with carboplatin, etoposide, doxorubicin, cyclophosphamide (cedc) and ifosfamide, carboplatin, etoposide (ice) regimen exclusion criteria: * patients with organ dysfunction (creatinine \> 2mg/dl, ejection fraction \<40% or severe arrhythmia/conduction disorder, other severe organ dysfunction) * hypersensitivity to pegteograstim, protein originated from e-coli, pegfilgrastim, filgrastim or latex. * patients with bleeding tendency to whom subcutaneous injection should be avoided. * active infection or infectious fever during the screening period. * genetic problem to fructose tolerance. * patients who participated in other clinical trial within 4 weeks before enrollment. * pregnant and nursing women
tumour necrosis factor release in locally advanced breast cancer patients receiving neoadjuvant docetaxel

Conditions: Breast Cancer

Summary: the purpose of this study is to assess the fine needle aspiration methodology in collecting sufficient tumour cells to measure tissue tnfa levels serially in human breast cancer sample receiving taxane treatment

this pilot study will begin to test the clinical relevance of the tnfa pathway in docetaxel response in breast cancer patients receiving taxane chemotherapy. - assess whether docetaxel can induce tnfa expression in breast cancer patients being treated with docetaxel

Eligibility criteria:
inclusion criteria: * biopsy proven labc, locally advanced breast cancer. (operable or non-operable) * any t3/t4 or n2, n3 clinical tnm stage breast cancer without metastases * ecog performance status of 0, 1 or 2. * patients should be able to comprehend the letter of information and be capable of giving informed consent. * female age 18 years old * history and physical * negative serum pregnancy test for women of child bearing age exclusion criteria: * inflammatory cancer (as defined by clinical evidence of dermal-lymphatic tumour involvement.) * ineligible for chemotherapy * patients with metastatic disease. * patients who have received prior chemotherapy or radiotherapy for this or any other malignancy. * previous breast cancer diagnosis * pregnant or lactating females are ineligible. * female patients of reproductive potential who decline to employ an adequate contraceptive method are ineligible. * participation in any concomitant trials.

Keywords: locally advanced breast cancer patients
influence of sensory electrical stimulation on hand functions in chronic stroke patients

Conditions: Stroke; Hand Functionality

Summary: this study investigates the impact of sensory electrical nerve stimulation (sens) on hand function in chronic stroke patients. thirty participants were randomly divided into two groups: study group (a): received sens combined with task-specific training. control group (b): received only task-specific training. assessments conducted before and after the intervention included measurements of grip strength, pinch strength, wrist range of motion, and performance on the action research arm test (arat).

this study explores the effectiveness of sensory electrical nerve stimulation (sens) in enhancing hand function among chronic stroke patients. thirty participants were randomly divided into two groups: study group (a): received sens combined with task-specific training. control group (b): received only task-specific training. assessment methods: before and after the intervention, both groups underwent evaluations using: grip dynamometer: to measure grip strength. pinch dynamometer: to assess pinch strength. digital goniometer: to determine wrist flexion and extension range of motion. action research arm test (arat): to evaluate upper limb functional performance.

Eligibility criteria:
inclusion criteria: * patients who have experienced their first-ever ischemic stroke in the carotid system domain. * age range: 40 to 65 years old. * duration of illness: 30 to 180 days since stroke onset. * spasticity of the affected hand muscles (wrist flexors, finger flexors, and finger adductors) must be grade 1+ or less according to the modified ashworth scale. * hand dysfunction severity ranges from mild to severe, defined by a score of ≤ 4 on the medical research council scale. exclusion criteria: * presence of a deformity in the paralytic upper limb before the stroke. * history of a lower motor neuron lesion in the impaired upper extremity (e.g., polyneuropathy) before the stroke. * skin abrasions or ulcerations on the affected upper limb. * unstable health conditions, including cardiac dysfunction, end-stage renal failure, unstable diabetes, or uncontrolled hypertension (\>190/110). * presence of a pacemaker or other implanted electrically sensitive devices. * significant orthopedic conditions or chronic pain syndromes. * chronic use of medications that may influence motor or sensory excitability (e.g., anti-epileptic or antipsychotic drugs). * pregnancy.

Keywords: stroke hand function sensory electrical nerve stimulation task specific training
study of esophageal squamous dysplasia prevalence at tenwek hospital

Conditions: Esophageal Dysplasia

Summary: esophageal squamous cell cancer (escc) is common in the developing world, and is the leading cancer diagnosis at tenwek hospital in southwestern kenya. the investigators long-term goal is to understand the pathogenesis and risk factors for escc in kenya, and to establish effective screening and prevention programs. the investigators hypothesize that asymptomatic esophageal squamous dysplasia (esd) is common in their region, and the current protocol is designed to determine the prevalence of esd in residents of southwestern kenya.

the prevalence of esophageal squamous dysplasia will be determined after evaluating pathology reports from unstained lesions and normal biopsies after staining with lugol's iodine.

Eligibility criteria:
inclusion criteria: * age ≥ 20 years * no dysphagia (subjects will be asked "do you have trouble swallowing food or water? do they get stuck inside after you swallow?" in their primary language exclusion criteria: * cardiac, respiratory, or metabolic disease that would increase the risk of endoscopy: history of myocardial infarction, arrhythmias, chronic obstructive pulmonary disease, diabetes, allergy to lidocaine. * unable or unwilling to provide informed consent.

Keywords: dysplasia esophageal squamous cell carcinoma
retrospective data collection: post study treatment anticancer therapy from imelda mo22223

Conditions: Breast Cancer

Summary: this study aims to understand better the effective results from the imelda mo22223 p-trial (nct00929240) and see if the anti-cancer therapies given during its follow-up time after study treatments were terminated possibly had an effect on efficacy results.


Eligibility criteria:
inclusion criteria: having been randomized in the imelda mo22223 p-trial exclusion criteria: not having been randomized in the imelda mo22223 p-trial
evaluation of bone parameters in patients with patello-femoral disorders

Conditions: Patello Femoral Syndrome

Summary: the aim of the study is to compare, in patients with patellofemoral joint disorders, the values related to the bone indexes of this joint, obtained from ct performed both in orthostatism and clinostatism

the aim of the study is to compare, in patients with patellofemoral joint disorders, the values related to the bone indexes of this joint, obtained from ct performed both in orthostatism and clinostatism. young patients with patellofemoral joint pathology, for which a diagnostic examination is necessary in order to determine a possible surgical indication, will be included in this pilot study, and will be evaluated using the "cone beam computed tomography "(cbct), a machine that use a low dose of radiation compared to traditional ct systems, and allows the examination in supine and standing position knee . in this way, for the same patient it will be possible to calculate the bone indexes both in weight-bearing condition and in non-weight-bearing, comparing the values between them, to identify possible differences due to the influence of orthostatism.

Eligibility criteria:
inclusion criteria: 1. male or female patients, between 18 and 50; 2. pathology or suspected patellofemoral joint pathology in which a ct examination is required for a diagnostic examination; 3. signature of informed consent. exclusion criteria: 1. patients incapable of understanding and will; 2. pregnant women; 3. patients with history of previous fractures of the knee. 4. bmi\> 40.

Keywords: ct
cognitive behavioural therapy for the treatment of late life depression

Conditions: Late-life Depression; Major Depressive Disorder; Major Depressive Episode; Major Depressive Disorder, Recurrent

Summary: this study addresses the unmet medical problem of insufficient treatment of late life depression (lld). compared with depression in early adulthood, treatment options of lld are limited. this trial is the first confirmatory multicentre study to test the efficacy of an lld-adapted cognitive behavioural therapy (cbt) program. it will test the hypothesis, that lld-specific cognitive behavioural therapy (cbt) is superior to unspecific supportive intervention (sui) with regard to reducing symptoms of depression over the course of 6 months. secondary goals are to test the efficacy of lld-cbt in comparison with sui on patient reported outcome in major depressive disorders (pro-mdd), anxiety, cognition, quality of life, overall health status, sleep and global clinical impression.


Eligibility criteria:
inclusion criteria: * out-patient status * male or female, age ≥ 60 years * ability to provide informed consent and written informed consent signed * dsm-5 diagnosis of a major depressive disorder/mdd (depressive episode at least moderate to severe) * score of at least 10 on the geriatric depression scale (gds) * score of at least 10 on the quick inventory of depressive symptomatology - clinician rating (qids-c) * score of at least 25 in the mini-mental-status-test (mmst) * no or stable (≥ 6 weeks) antidepressive pharmacological treatment at baseline (medication will be kept stable at least throughout the 8 weeks of treatment). * sufficient german language skills exclusion criteria: * bipolar depression * schizophrenia or other psychotic disorders * substance abuse or dependency * dementia * acute suicidality * anxiety disorder as stand-alone diagnosis (e.g. generalized anxiety disorder, panic disorder, social phobia) * obsessive-compulsive disorder (ocd) as stand-alone diagnosis * participation in any another clinical trial parallel to this trial * additional psychological/psychotherapeutic treatment throughout the 8-week treatment period * regular use with scheduled daily dosing of benzodiazepines (not prn) during 8-week treatment * severe or instable medical condition, which clearly impacts on depression or on the ability to participate in the trial * brain disease with severe functional impairment that impacts the ability to participate in the trial (e.g. aphasia, parkinson's disease)

Keywords: late-life depression psychotherapy major depression randomized controlled trial treatment